Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease

The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress

(2022) Boris Decourt et al.   Aging and Disease

A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer’s Disease Mice

(2022) Fadi Rofo et al.   Neurotherapeutics

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

(2021) Malin Johannesson et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty

(2020) Nurul Husna Ibrahim et al.   Frontiers in Pharmacology

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

(2020) Martin Tolar et al.   Alzheimers Research & Therapy

AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial)

(2020) Paul S. Aisen et al.   Alzheimers & Dementia

Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

(2018) Christopher H. van Dyck   BIOLOGICAL PSYCHIATRY

The Unexpected Role of Aβ1-42 Monomers in the Pathogenesis of Alzheimer’s Disease

(2018) Elena Tamagno et al.   JOURNAL OF ALZHEIMERS DISEASE

Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain

(2018) Kristina Magnusson et al.   JOURNAL OF ALZHEIMERS DISEASE

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

(2018) Stina Tucker et al.   JOURNAL OF ALZHEIMERS DISEASE

Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies

(2017) Jun Zhao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2016) Ross Penninkilampi et al.   Journal of Neuroimmune Pharmacology

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation

(2012) Dag Sehlin et al.   PLoS One

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Hydrogen sulfide reduces mRNA and protein levels of beta-site amyloid precursor protein cleaving enzyme 1 in PC12 cells

(2010) Hua Zhang et al.   NEUROCHEMISTRY INTERNATIONAL

Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-Aβ Antibodies

(2010) Dag Sehlin et al.   Neurodegenerative Diseases

An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease

(2009) Anna Lord et al.   NEUROBIOLOGY OF DISEASE